To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?
Year: 2025
Type: article
Study design: Case Report
Abstract: We report the occurrence of low-level hepatitis B virus (HBV) viremia in people with HIV with controlled CD4 counts and isolated core antibody reactivity switched to long-acting injectable cabotegravir/rilpivirine. This series raises questions about the reintroduction of anti-HBV medications, presents the variation of several HBV markers alongside HBV-DNA and reveals an effective spontaneous immune response.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofaf266
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
OpenAlex ID: W4410106717